286 related articles for article (PubMed ID: 25476932)
1. miR-205 acts as a tumour radiosensitizer by targeting ZEB1 and Ubc13.
Zhang P; Wang L; Rodriguez-Aguayo C; Yuan Y; Debeb BG; Chen D; Sun Y; You MJ; Liu Y; Dean DC; Woodward WA; Liang H; Yang X; Lopez-Berestein G; Sood AK; Hu Y; Ang KK; Chen J; Ma L
Nat Commun; 2014 Dec; 5():5671. PubMed ID: 25476932
[TBL] [Abstract][Full Text] [Related]
2. ATM-mediated stabilization of ZEB1 promotes DNA damage response and radioresistance through CHK1.
Zhang P; Wei Y; Wang L; Debeb BG; Yuan Y; Zhang J; Yuan J; Wang M; Chen D; Sun Y; Woodward WA; Liu Y; Dean DC; Liang H; Hu Y; Ang KK; Hung MC; Chen J; Ma L
Nat Cell Biol; 2014 Sep; 16(9):864-75. PubMed ID: 25086746
[TBL] [Abstract][Full Text] [Related]
3. MiR-200c suppresses TGF-β signaling and counteracts trastuzumab resistance and metastasis by targeting ZNF217 and ZEB1 in breast cancer.
Bai WD; Ye XM; Zhang MY; Zhu HY; Xi WJ; Huang X; Zhao J; Gu B; Zheng GX; Yang AG; Jia LT
Int J Cancer; 2014 Sep; 135(6):1356-68. PubMed ID: 24615544
[TBL] [Abstract][Full Text] [Related]
4. Downregulated microRNA-200a promotes EMT and tumor growth through the wnt/β-catenin pathway by targeting the E-cadherin repressors ZEB1/ZEB2 in gastric adenocarcinoma.
Cong N; Du P; Zhang A; Shen F; Su J; Pu P; Wang T; Zjang J; Kang C; Zhang Q
Oncol Rep; 2013 Apr; 29(4):1579-87. PubMed ID: 23381389
[TBL] [Abstract][Full Text] [Related]
5. MiR-200 can repress breast cancer metastasis through ZEB1-independent but moesin-dependent pathways.
Li X; Roslan S; Johnstone CN; Wright JA; Bracken CP; Anderson M; Bert AG; Selth LA; Anderson RL; Goodall GJ; Gregory PA; Khew-Goodall Y
Oncogene; 2014 Jul; 33(31):4077-88. PubMed ID: 24037528
[TBL] [Abstract][Full Text] [Related]
6. 53BP1 suppresses epithelial-mesenchymal transition by downregulating ZEB1 through microRNA-200b/429 in breast cancer.
Kong X; Ding X; Li X; Gao S; Yang Q
Cancer Sci; 2015 Aug; 106(8):982-9. PubMed ID: 26011542
[TBL] [Abstract][Full Text] [Related]
7. The EMT-activator ZEB1 promotes tumorigenicity by repressing stemness-inhibiting microRNAs.
Wellner U; Schubert J; Burk UC; Schmalhofer O; Zhu F; Sonntag A; Waldvogel B; Vannier C; Darling D; zur Hausen A; Brunton VG; Morton J; Sansom O; Schüler J; Stemmler MP; Herzberger C; Hopt U; Keck T; Brabletz S; Brabletz T
Nat Cell Biol; 2009 Dec; 11(12):1487-95. PubMed ID: 19935649
[TBL] [Abstract][Full Text] [Related]
8. Loss of MicroRNA-101 Promotes Epithelial to Mesenchymal Transition in Hepatocytes.
Zhao S; Zhang Y; Zheng X; Tu X; Li H; Chen J; Zang Y; Zhang J
J Cell Physiol; 2015 Nov; 230(11):2706-17. PubMed ID: 25808945
[TBL] [Abstract][Full Text] [Related]
9. miR-139-5p inhibits epithelial-mesenchymal transition, migration and invasion of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.
Qiu G; Lin Y; Zhang H; Wu D
Biochem Biophys Res Commun; 2015 Jul; 463(3):315-21. PubMed ID: 26022123
[TBL] [Abstract][Full Text] [Related]
10. MiR-652 inhibits acidic microenvironment-induced epithelial-mesenchymal transition of pancreatic cancer cells by targeting ZEB1.
Deng S; Li X; Niu Y; Zhu S; Jin Y; Deng S; Chen J; Liu Y; He C; Yin T; Yang Z; Tao J; Xiong J; Wu H; Wang C; Zhao G
Oncotarget; 2015 Nov; 6(37):39661-75. PubMed ID: 26498682
[TBL] [Abstract][Full Text] [Related]
11. Loss of the polycomb protein Mel-18 enhances the epithelial-mesenchymal transition by ZEB1 and ZEB2 expression through the downregulation of miR-205 in breast cancer.
Lee JY; Park MK; Park JH; Lee HJ; Shin DH; Kang Y; Lee CH; Kong G
Oncogene; 2014 Mar; 33(10):1325-35. PubMed ID: 23474752
[TBL] [Abstract][Full Text] [Related]
12. miR-1271 inhibits migration, invasion and epithelial-mesenchymal transition by targeting ZEB1 and TWIST1 in pancreatic cancer cells.
Liu H; Wang H; Liu X; Yu T
Biochem Biophys Res Commun; 2016 Apr; 472(2):346-52. PubMed ID: 26940738
[TBL] [Abstract][Full Text] [Related]
13. miR-205 enhances radiation sensitivity of prostate cancer cells by impairing DNA damage repair through PKCε and ZEB1 inhibition.
El Bezawy R; Tinelli S; Tortoreto M; Doldi V; Zuco V; Folini M; Stucchi C; Rancati T; Valdagni R; Gandellini P; Zaffaroni N
J Exp Clin Cancer Res; 2019 Feb; 38(1):51. PubMed ID: 30717752
[TBL] [Abstract][Full Text] [Related]
14. Therapeutic Delivery of miR-29b Enhances Radiosensitivity in Cervical Cancer.
Zhang T; Xue X; Peng H
Mol Ther; 2019 Jun; 27(6):1183-1194. PubMed ID: 31029553
[TBL] [Abstract][Full Text] [Related]
15. Pterostilbene inhibits triple-negative breast cancer metastasis via inducing microRNA-205 expression and negatively modulates epithelial-to-mesenchymal transition.
Su CM; Lee WH; Wu AT; Lin YK; Wang LS; Wu CH; Yeh CT
J Nutr Biochem; 2015 Jun; 26(6):675-85. PubMed ID: 25792283
[TBL] [Abstract][Full Text] [Related]
16. Coordinated regulation of β-tubulin isotypes and epithelial-to-mesenchymal transition protein ZEB1 in breast cancer cells.
Lobert S; Graichen ME; Morris K
Biochemistry; 2013 Aug; 52(32):5482-90. PubMed ID: 23869586
[TBL] [Abstract][Full Text] [Related]
17. Dual regulation by microRNA-200b-3p and microRNA-200b-5p in the inhibition of epithelial-to-mesenchymal transition in triple-negative breast cancer.
Rhodes LV; Martin EC; Segar HC; Miller DF; Buechlein A; Rusch DB; Nephew KP; Burow ME; Collins-Burow BM
Oncotarget; 2015 Jun; 6(18):16638-52. PubMed ID: 26062653
[TBL] [Abstract][Full Text] [Related]
18. microRNA-200c modulates the epithelial-to-mesenchymal transition in human renal cell carcinoma metastasis.
Wang X; Chen X; Wang R; Xiao P; Xu Z; Chen L; Hang W; Ruan A; Yang H; Zhang X
Oncol Rep; 2013 Aug; 30(2):643-50. PubMed ID: 23754305
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA-200C and -150 play an important role in endothelial cell differentiation and vasculogenesis by targeting transcription repressor ZEB1.
Luo Z; Wen G; Wang G; Pu X; Ye S; Xu Q; Wang W; Xiao Q
Stem Cells; 2013 Sep; 31(9):1749-62. PubMed ID: 23765923
[TBL] [Abstract][Full Text] [Related]
20. MicroRNA-200b regulates cell proliferation, invasion, and migration by directly targeting ZEB2 in gastric carcinoma.
Kurashige J; Kamohara H; Watanabe M; Hiyoshi Y; Iwatsuki M; Tanaka Y; Kinoshita K; Saito S; Baba Y; Baba H
Ann Surg Oncol; 2012 Jul; 19 Suppl 3():S656-64. PubMed ID: 22311119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
